• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Testing Neurofeedback for ADHD
Research Update

Testing Neurofeedback for ADHD

April 1, 2023
Alicia Watson, MD
From The Carlat Child Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Alicia Watson, MD. Dr. Watson has no financial relationships with companies related to this material.

REVIEW OF: Neurofeedback Collaborative Group, J Am Acad Child Adolesc Psychiatry 2021;60(7):841–855

STUDY TYPE: Randomized controlled trial

Does neurofeedback (NF) reduce symptoms of ADHD? A meta-analysis of small studies demonstrated gains for inattention and hyperactivity-impulsivity that persisted at six-month follow-up (Van Doren J et al, Eur Child Adolesc Psychiatry 2019;28(3):293–305). A randomized controlled trial found that NF was more effective than computerized attention skills training; however, it did not use a standard protocol (Gevensleben H et al, J Child Psychol Psychiatry 2009;50(7):780–789). The authors of the present study wanted to give NF a more thorough test.

In this randomized, double-blind, placebo-controlled trial, researchers assigned 84 children with ADHD to the active NF group and 58 to the control group. Subjects were 7–10 years old, and 111 were male. They were allowed to be on stimulants but no other psychiatric medication.

The treatment group received the theta/beta ratio protocol, one of several NF protocols for ADHD. Control group participants received sham NF. Both groups had a target of 38 treatments and received counseling on sleep and nutrition.

The primary outcome was parent and teacher Conners scores. Both groups had significant improvement from baseline, but there were no statistically significant differences between the active and sham groups at the end of the protocol or at 13-month follow-up.

The authors speculate that both groups may have benefitted from consistent attention to diet and sleep, the EMG biofeedback component that both received, or the reinforcement for an activity requiring attention. They plan to follow up again at 25 months.

Carlat Take

This is the first large-scale randomized clinical trial of NF for ADHD, and the results were disappointing. Some families may try it, but we don’t recommend referring your ADHD patients to this expensive treatment until studies show clearer benefit.

Child Psychiatry Research Update
KEYWORDS ADHD attention deficit hyperactivity disorder Controlled trial neurofeedback sham treatment the theta/beta ratio (TBR) protocol
    Alicia Watson, MD

    More from this author
    www.thecarlatreport.com
    Issue Date: April 1, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Autism in Children and Adolescents, CCPR, April/May/June 2023
    Treating Irritability in Autism: Functional and Medication Approaches
    Addressing Suicidality in Autistic Children and Teens
    Recognizing and Treating Psychosis in Autism
    Autistic Drivers Perform Well
    Testing Neurofeedback for ADHD
    Is It Worth Adding Coenzyme Q10 to Atomoxetine for ADHD?
    Does Treatment of ADHD Help Caregiver Stress?
    Stimulant Treatment Effect on Anxiety in ADHD
    Why Do So Many Pediatric Antidepressant Research Trials “Fail”?
    CME Post-Test, Autism in Children and Adolescents, CCPR, April/May/June 2023
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.